Publications

  1. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol. 2014 Nov 24.
    View PubMed
  2. Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, Petersen GM. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. Pancreas. 2014 Nov; 43(8):1219-22.
    View PubMed
  3. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J. 2014 Jun; 14(3):241-7. Epub 2013 Sep 03.
    View PubMed
  4. Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, Jacobson A, Grendahl D, Seisler D, Hobday T, Loprinzi CL. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014 May; 22(5):1313-7. Epub 2014 Jan 09.
    View PubMed
  5. Northfelt DW, Allred JB, Liu HS, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. American Journal Of Clinical Oncology-cancer Clinical Trials. 2014 Apr; 37(2):167-71.
  6. Kaur JS, Vierkant RA, Hobday T, Visscher D. Regional differences in breast cancer biomarkers in american Indian and Alaska native women. Cancer Epidemiol Biomarkers Prev. 2014 Mar; 23(3):409-15.
    View PubMed
  7. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat. 2013 Feb; 137(3):903-13. Epub 2013 Jan 10.
    View PubMed
  8. Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T, RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013; 18(1):46-53. Epub 2012 Dec 21.
    View PubMed
  9. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, for the North Central Cancer Treatment Group. Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer. Am J Clin Oncol. 2012 Dec 01. [Epub ahead of print]
    View PubMed
  10. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12(6):387-91. Epub 2012 Oct 17.
    View PubMed
  11. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23. Epub 2012 Jun 04.
    View PubMed
  12. Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol. 2012; 2012:973946. Epub 2012 Nov 25.
    View PubMed
  13. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat. 2011 Dec; 130(3):993-1002. Epub 2011 Jul 16.
    View PubMed
  14. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  15. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1; 29(7):934-43. Epub 2011 Jan 24.
    View PubMed
  16. Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, Garcia-Carbonero R, Carrato A. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2011 Mar; 30 Suppl 1:19-26.
    View PubMed
  17. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23.
    View PubMed
  18. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat. 2011 Feb; 126(1):215-20. Epub 2010 Oct 26.
    View PubMed
  19. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66. Epub 2011 Sep 20.
    View PubMed
  20. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 1; 28(1):69-76. Epub 2009 Nov 23.
    View PubMed
  21. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer. 2009 Mar; 8(2):88-93.
    View PubMed
  22. Walia T, Quevedo JF, Hobday TJ, Croghan G, Jatoi A. Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy. Ther Clin Risk Manag. 2008 Dec; 4(6):1363-6.
    View PubMed
  23. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008 Feb; 103(2):475-83; quiz 484. Epub 2007 Nov 19.
    View PubMed
  24. Stilling GA, Zhang H, Ruebel KH, Leontovich AA, Jin L, Tanizaki Y, Zhang S, Erickson LA, Hobday T, Lloyd RV. Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors. Endocr Pathol. 2007 Winter; 18(4):223-32.
    View PubMed
  25. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA. Carcinoid heart disease. Prog Cardiovasc Dis. 2007 May-Jun; 49(6):439-51.
    View PubMed
  26. Zhang HY, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA, Lloyd RV. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine. 2006 Dec; 30(3):299-306.
    View PubMed
  27. Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, Barnes SA, Gullerud RE, Hobday TJ, Farley DR. A single-center experience with inflammatory breast cancer, 1985-2003. Arch Surg. 2006 Jun; 141(6):567-72; discussion 572-3.
    View PubMed
  28. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl. 2006 Mar; 12(3):448-56.
    View PubMed
  29. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005 Oct; 18(10):1329-35.
    View PubMed
  30. Atwell TD, Charboneau JW, Que FG, Rubin J, Lewis BD, Nagorney DM, Callstrom MR, Farrell MA, Pitot HC, Hobday TJ. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005 Jul-Aug; 28(4):409-21.
    View PubMed
  31. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005 Apr; 80(4):502-6.
    View PubMed
  32. Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer. 2005 Apr; 5 Suppl 1:S11-8.
    View PubMed
  33. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control. 2005 Apr; 12(2):73-81.
    View PubMed
  34. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003 Dec; 78(12):1578-9.
    View PubMed
  35. Hobday TJ. The role of oxaliplatin/5-fluorouracil/leucovorin in the therapy of colorectal cancer. Adv Colorect Cancer. 2003; 7(1):3-6.
  36. Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook JE, O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol. 2002 Dec 1; 20(23):4574-80.
    View PubMed
  37. Hobday TJ, Goldberg RM. Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer. 2002 Nov; 2(3):161-9.
    View PubMed
  38. Hobday TJ, Erlichman C. Adjuvant therapy of colon cancer: a review. Clin Colorectal Cancer. 2002 Feb; 1(4):230-6.
    View PubMed
  39. Hobday TJ, Pellikka PA, Attenhofer Jost CH, Oh JK, Miller FA Jr, Seward JB. Chronotropic response, safety, and accuracy of dobutamine stress echocardiography in patients with atrial fibrillation and known or suspected coronary artery disease. Am J Cardiol. 1998 Dec 1; 82(11):1425-7, A9.
    View PubMed
  40. Hobday TJ, Heser JL, Rooke TW. The use of laser Doppler flowmetry and transcutaneous oxygen measurements to evaluate the efficacy of sympathectomy in the treatment of arterial occlusive disease. J Vasc Technol. 1994; 18:19-22.